重组人干扰素β-1a注射液对大鼠肝纤维化模型的治疗作用  

Therapeutical effect of human-interferon recombine β-1a injection on model of rats with hepatic fibrosis

作　　者：王妍[1] 林孝发[1] 张微微[2] 韦康[2] 王中汉 田建明[2] 

机构地区：[1]深圳职业技术学院,广东深圳518044 [2]吉林省中医药科学院,长春130021 [3]吉林大学第二临床医院,长春130041

出　　处：《长春中医药大学学报》2015年第5期904-907,共4页Journal of Changchun University of Chinese Medicine

基　　金：广东省教育厅项目(2012B091100408);深圳市科技创新委项目(CXZZ20120619162250509)

摘　　要：目的研究重组人干扰素β-1a注射液及白蛋白注射液对肝纤维化大鼠的治疗作用。方法通过给大鼠灌服50%的四氯化碳花生油溶液1 mL/kg,每周2-3次,5周后开始使用受试药物（隔日注射1次）,同时继续同上灌服50%的四氯化碳花生油溶液。9周后取血、取肝脏,测定血清ALT、AST、TP、ALB、TBIL,测定肝组织羟脯氨酸含量,并对肝脏做病理组织学检查。结果干扰素β-1a、白蛋白注射液均能明显降低肝纤维化模型大鼠血清的ALT、AST、TBIL,能明显升高肝纤维化大鼠血清ALB、ALB/GLB,且能明显降低肝纤维化大鼠肝组织羟脯氨酸含量。结论干扰素β-1a、白蛋白注射液对肝纤维化模型大鼠的肝纤维化程度均有明显的抑制作用。Objective To analyze the therapeutical effect of human-interferon recombine β-1a injectio and the albumin injectio on the rats hepatic fibrosis. Methods Feed rats with 50% solutions of CCl peanut oil 1 mL/kg,2-3times/week,use the testing drugs after 5 weeks（ alternates day per times）,and at the same time continuously feed the rats with 50% solutions of CCl peanut oil. Sample the blood and liver after 9 weeks and measure ALT,AST,TP,ALB,TBIL of the blood plasma and the Hyp of the liver tissue,and undertake the histopathology of the liver tissue. Results Human-interferon recombine β-1a injectio and the albumin injectiocan obviously decrease the ALT,AST,TBIL of blood plasma of the model of the hepatic fibrosis rats evidently,and increase Hyp of the liver tissue of the model of the hepatic fibrosis rats at the meantime. Conclusi on Human-interferon recombine β-1a injectio and the albumin injectio can inhibit the level of the hepatic fibrosis of the model rats.

关 键 词：重组人干扰素β-1a注射液 白蛋白注射液 大鼠肝纤维化模型 

分 类 号：R963[医药卫生—微生物与生化药学]